Cancer Moonshot

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association

Retrieved on: 
Mardi, avril 30, 2024
Oncology, Health, Other Health, General Health, Research, Science, Pharmaceutical, FDA, Executive, Cancer Moonshot, The Learning Lab, Immunotherapy, Carcinoma in situ, BCG, Deep diving, CIS, Patient, Cancer, Medicine, NMIBC, AUA, Bacillus, Neoplasm, Learning Lab, Bladder cancer, NK, Vaccine

“The realization that this transformation of MHC- to MHC+ could rescue exhausted or immune-evaded T cells was the basis of our Cancer Moonshot announced in 2016 .

Key Points: 
  • “The realization that this transformation of MHC- to MHC+ could rescue exhausted or immune-evaded T cells was the basis of our Cancer Moonshot announced in 2016 .
  • I very much look forward to elaborating on the details with Dr. Sam Chang at the AUA conference,” said Dr. Patrick Soon-Shiong.
  • Hosting Dr. Soon-Shiong will be Dr. Sam S. Chang, M.D., Professor of Urology and Chief Surgical Officer of the Vanderbilt Ingram Cancer Center.
  • Dr. Chang was a principal investigator for ImmunityBio’s QUILT 3.032 study, which produced the data on which the FDA approval was based.

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer

Retrieved on: 
Jeudi, avril 25, 2024
Oncology, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Cancer, RWE, EDT, Cancer Moonshot, Lung cancer, Hope, Nivolumab, American Urological Association, Second, Pembrolizumab, Survival, Immunotherapy, American Cancer Society, Webcast, BCG, Disease, Patient, Medicine, AUA, Multimedia, Death, NK, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240424428572/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240424428572/en/
    In NSCLC patients who relapsed or were refractory to checkpoint inhibitors, ANKTIVA was administered together with the same checkpoint inhibitor.
  • The addition of ANKTIVA resulted in the rescue of the checkpoint therapy efficacy, with significant prolongation of overall survival.
  • This prolongation of survival in NSCLC following checkpoint failure is consistent with ImmunityBio’s findings of durable complete responses following BCG failure in NMIBC.
  • According to the American Cancer Society, lung cancer is the second most common cancer in the U.S.

HealthWell Foundation Invited to Participate in The White House Minority Health Forum

Retrieved on: 
Jeudi, avril 18, 2024
Technology policy, Forum, Cancer Moonshot, Federation, Policy, Patient, Physician, Private sector, Pharmaceutical industry

GERMANTOWN, Md., April 18, 2024 /PRNewswire/ -- The HealthWell Foundation®, an independent non-profit charitable organization that provides financial assistance for underinsured Americans, is honored to announce its participation in the White House Minority Health Forum taking place today, April 18, 2024. Alan Klein, HealthWell Foundation Chief Development Officer, will attend the Forum and participate in the breakout session: Making Innovation & Research Work for Everyone.

Key Points: 
  • GERMANTOWN, Md., April 18, 2024 /PRNewswire/ -- The HealthWell Foundation®, an independent non-profit charitable organization that provides financial assistance for underinsured Americans, is honored to announce its participation in the White House Minority Health Forum taking place today, April 18, 2024.
  • Alan Klein, HealthWell Foundation Chief Development Officer, will attend the Forum and participate in the breakout session: Making Innovation & Research Work for Everyone.
  • The White House Minority Health Forum aims to highlight progress, discuss challenges, and identify new actions from the federal government and the private sector to improve health outcomes and reduce health inequities.
  • "We were honored by The White House Office of Science and Technology Policy's invitation to take part in this critical discussion among key health leaders," said HealthWell Foundation Board Chair, David L. Knowlton.

White House declares April 2024 as Cancer Prevention and Early Detection Month

Retrieved on: 
Vendredi, mars 29, 2024
Health, Organization, Partnership, Cancer, Cancer Moonshot, Risk, Family, Birth control

Alexandria, Va., March 29, 2024 (GLOBE NEWSWIRE) -- The White House today issued an official presidential proclamation declaring April 2024 as the inaugural National Cancer Prevention and Early Detection Month.

Key Points: 
  • Alexandria, Va., March 29, 2024 (GLOBE NEWSWIRE) -- The White House today issued an official presidential proclamation declaring April 2024 as the inaugural National Cancer Prevention and Early Detection Month.
  • The designation of National Cancer Prevention and Early Detection Month is a collaborative effort spearheaded by the Prevent Cancer Foundation and supported by 84 organizations.
  • This awareness month is a critical step toward reducing the impact of cancer on individuals, families and communities across the U.S.
    “I’m immensely proud of the Foundation for leading a herculean effort in partnership with the White House Cancer Moonshot team to officially recognize April 2024 as the first-ever National Cancer Prevention and Early Detection Month,” says Jody Hoyos, CEO of the Prevent Cancer Foundation.
  • Highlighting progress: Celebrating the tremendous progress made in cancer research and the development of innovative prevention and early detection strategies driven forward by the Cancer Moonshot.

123 Leading Organizations Urge President Biden: Act Now to Eliminate Menthol Cigarettes

Retrieved on: 
Jeudi, mars 21, 2024
Health, Organization, Tobacco industry, The Washington Post, Tobacco, Health equity, Public, African Americans, Research, Delays, Cancer, Death, Cancer Moonshot, Woman, Smoking, Administration, FDA

Act now to eliminate menthol cigarettes," the ad states.

Key Points: 
  • Act now to eliminate menthol cigarettes," the ad states.
  • Menthol cigarettes are a "starter product" for youth because menthol cools and numbs the throat, masking the harshness of tobacco smoke.
  • Researchers estimate that prohibiting menthol cigarettes will save up to 654,000 lives within 40 years, including 255,000 Black lives.
  • Given these enormous benefits, the Biden Administration has an obligation to issue the final rules prohibiting menthol cigarettes and flavored cigars without further delay.

MEDITECH to Spotlight Intelligent Interoperability at HIMSS24

Retrieved on: 
Jeudi, mars 7, 2024
Technology, Nanotechnology, Health, Other Health, Artificial Intelligence, Practice Management, Medical Devices, Software, Managed Care, Hospitals, Genetics, Hardware, Data Management, Nursing, Cloud, Google Cloud, FDB, Cardiac catheterization, AI, Structuring, Intelligence, API, Pharmacogenomics, Clinical trial, Cancer Moonshot, FHIR, EHR, SMART, Patient, MEDITECH, OLIS, Electronic health record, FAST, Representational state transfer

As a longtime interoperability leader and advocate, MEDITECH is once again excited to feature its latest interoperability innovations in the HIMSS Interoperability Showcase.

Key Points: 
  • As a longtime interoperability leader and advocate, MEDITECH is once again excited to feature its latest interoperability innovations in the HIMSS Interoperability Showcase.
  • MEDITECH will present its interoperability strategy at the Interoperability Showcase Spotlight Theater on Wednesday, March 13 at 11:15 a.m. in the “Intelligent Interoperability” session.
  • “Intelligent interoperability opens the doors to innovation by leveraging the flexibility and scalability of the cloud , along with modern and open data standards like SMART apps and FHIR APIs.
  • MEDITECH will also share its Canadian interoperability strategy at the “Achieving a Collaborative Approach to Meaningful Interoperability Across Canada” session.

British Technology company, C the Signs, selected by the White House-Backed Accelerator Programme, CancerX, to half Cancer Deaths

Retrieved on: 
Mardi, février 27, 2024
Cancer Moonshot, AstraZeneca, Intel, Atrium Health, National Health Service, Quality of life, Hope, White, Risk, Social work, NHS, Health care, UC, Business, Patient, Accelerator, Dell Technologies, NHS England, Disease, Heart, Healthcare UK, Mortality, AWS, Cancer, Pharmaceutical industry

CancerX was unveiled by the White House in a landmark announcement last year to spearhead innovation in oncology.

Key Points: 
  • CancerX was unveiled by the White House in a landmark announcement last year to spearhead innovation in oncology.
  • The CancerX Accelerator programme aims to promote and fortify digital innovations in oncology by providing promising startups an opportunity to collaborate with leading cancer organizations.
  • C the Signs is an AI cancer prediction platform that identifies patients at risk of cancer at the earliest and most curable stage of the disease.
  • Launched by the White House, this initiative marks a significant step toward realizing the Cancer Moonshot's vision of a 50% reduction in cancer mortality.

British Technology company, C the Signs, selected by the White House-Backed Accelerator Programme, CancerX, to half Cancer Deaths

Retrieved on: 
Mardi, février 27, 2024
Cancer Moonshot, AstraZeneca, Intel, Atrium Health, National Health Service, Quality of life, Hope, White, Risk, Social work, NHS, Health care, UC, Business, Patient, Accelerator, Dell Technologies, NHS England, Disease, Heart, Healthcare UK, Mortality, AWS, Cancer, Pharmaceutical industry

CancerX was unveiled by the White House in a landmark announcement last year to spearhead innovation in oncology.

Key Points: 
  • CancerX was unveiled by the White House in a landmark announcement last year to spearhead innovation in oncology.
  • The CancerX Accelerator programme aims to promote and fortify digital innovations in oncology by providing promising startups an opportunity to collaborate with leading cancer organizations.
  • C the Signs is an AI cancer prediction platform that identifies patients at risk of cancer at the earliest and most curable stage of the disease.
  • Launched by the White House, this initiative marks a significant step toward realizing the Cancer Moonshot's vision of a 50% reduction in cancer mortality.

CancerX Announces Inaugural Start-Up Accelerator Cohort

Retrieved on: 
Lundi, février 26, 2024
Honey, Toxicity, AstraZeneca, Blue box, Government, National Cancer Institute, HHS, Organization, Diagnosis, Estate (law), Assistant, Cancer Moonshot, Navya, White, ViVe, Dime, MassChallenge, AWS, Partnership, Mentorship, Cancer, Dell Technologies, Research, CMMI, Intel, NCI, FDA, Senior advisor, Medicare, Executive, Accelerator, ONC, Pharmaceutical industry

BOSTON, Feb. 26, 2024 /PRNewswire/ -- Today on the Central Stage at ViVE 2024, CancerX announced the 16 start-up members of its inaugural Accelerator cohort, launched in partnership with MassChallenge: The Blue Box, C the Signs, Cancer Insights, Curvia, EnteroTrack, Gesund.ai, Gray Oncology, LindAI, Mika Health, Navya, Oatmeal Health, Orbit Genomics, Realyze Intelligence, Reimagine Care, SurvivorPlan, and Xanthos. 

Key Points: 
  • The collaborative environment fostered by this unique Accelerator will promote cross-pollination of ideas within cohort, spurring further innovation."
  • "We are proud to be the first to formalize the support for early-stage digital innovation in oncology through the CancerX Accelerator.
  • CancerX will build on the success of the inaugural round and plans to open Accelerator applications for a second cohort in the fall of this year.
  • For more information about the CancerX Accelerator and updates on future cohorts, please visit the website or sign up to receive CancerX newsletters.

Innsena Announces Impact Partnership with CancerX

Retrieved on: 
Mardi, février 13, 2024
Technology, Research, Consulting, Other Technology, Health Technology, Professional Services, Health, Science, Oncology, Toxicity, Assistant, Cancer Moonshot, Death, Organization, Public, Patient, Dime, Disease, Insurance, Medicaid, Movement, ONC, Cancer, Partnership, Pharmaceutical industry

Innsena , a health tech consultancy focused on improving care outcomes for underserved communities, today announced its partnership with CancerX , a public-private partnership announced by The White House as a national accelerator to boost digital innovation in the fight against cancer as part of the reignited Cancer Moonshot .

Key Points: 
  • Innsena , a health tech consultancy focused on improving care outcomes for underserved communities, today announced its partnership with CancerX , a public-private partnership announced by The White House as a national accelerator to boost digital innovation in the fight against cancer as part of the reignited Cancer Moonshot .
  • Innsena joins the initiative as its first Impact Supporter.
  • As a CancerX Impact Partner, Innsena will work collaboratively with the public-private partnership to advise on health disparities, the needs of the underserved, access to care and rural and tribal community, and other needs as its programs evolve.
  • “We’re grateful Innsena has chosen to join the CancerX community,” says Jennifer Goldsack, CEO of the Digital Medicine Society (DiMe) , co-host of CancerX.